Newsletter | August 12, 2026

08.12.26 -- From Breadth To Expertise: The Changing Priorities Of Drug Sponsors

SPONSOR

Outsourced Pharma Capabilities Update: Nanoparticles (Aug. 18, 2026, 11:00 AM ET)

This session explores why nanoparticle programs succeed or stall. Experts examine how early formulation decisions—such as lipid composition, particle engineering, and process design—impact scalability, tech transfer, and commercialization. Learn how CDMO strategies influence risk, uncover hidden tradeoffs, and identify early signals of downstream challenges to improve development timelines and manufacturing outcomes for advanced nanoparticle therapeutics. Register here.

INDUSTRY INSIGHTS

Global Trials, Zero Delays: Rethinking Clinical Logistics

This comprehensive guide provides practical insights and best practices for ensuring the timely, secure, and reliable delivery of clinical trial materials worldwide.

Navigating Nitrosamine Impurities In Pharmaceutical Drug Development

Understanding formation mechanisms and potency categorization allows developers to mitigate risks early, ensuring regulatory compliance and patient safety without compromising product performance.

Patient Adherence With A Novel Dosage Form

A sprinkle formulation helps patients with tremors or dysphagia take medication more easily, improving adherence, comfort, and care through a novel, FDA-approved oral granule format.

FEATURED EDITORIAL

From Breadth To Expertise: The Changing Priorities Of Drug Sponsors

CDMO mergers and acquisitions and the addition of services has been a dominating trend in outsourcing; comprehensive offerings and scale are proclaimed indispensable to customers. Sufficient time has now elapsed so we can evaluate this era of more and those claims.  Chief Editor Louis Garguilo looks into the evidence, and comes up with some interesting developments.

The CDMO Intelligence Report: Opportunities, Threats, And Market Signals

Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections.

INDUSTRY INSIGHTS CONTINUED

How AI And Automation Are Impacting Process Development

Review the mountain of data behind every process development program — and why AI's real promise is surfacing the right piece of it at the moment a team needs to decide.

Beyond The Booth: Shaping The Future Of Pharma Partnerships

Navigating the pharmaceutical landscape requires a focus on supply chain, partnership models, and practical AI adoption. Understanding these key trends is essential for ensuring long-term stability.

Beyond Pills: The Rise Of Liquid Suspensions For Complex Formulations

Accelerate the development of liquid suspensions and bring patient-centric formulations from concept to commercialization by leveraging specialized expertise, advanced technologies, and dedicated facilities.

Why Emerging Drug Developers Can't Afford To Delay Development

Rushing early pharma development by neglecting quality and analytical frameworks risks regulatory failures, clinical holds, and expensive rework.

Introducing Devices Earlier To Streamline The DDC Journey

Uncover how early device strategy and integrated planning can streamline development, reduce risk, and accelerate your path to commercial success.

What's Hot In Freeze Drying? Your Lyophilization Questions Answered

Improve lyophilization outcomes by optimizing formulation, cycle parameters, and scale-up strategies to reduce variability and enhance stability across development.

SOLUTIONS

Precision You Can Trust

Functional VPA Copolymer

Small Molecule Development With AI-Powered Early Phase Strategies

Clinical Trial Services

OUTSOURCED PHARMA CAPABILITIES UPDATE

Find Your New CDMO At Outsourced Pharma Capabilities Update

CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capabilities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs.

Connect With Outsourced Pharma: